Dr. Ravi Vij, MD

Dr. Vij practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Vij's NPI, 1023034337, was assigned on July 14, 2006. Dr. Vij holds Missouri license 110997.

Dr. Vij's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Vij also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Vij's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Vij is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Vij to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vij practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Vij's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Vij is licensed in Missouri.

CMS data shows 11,911 Medicare services from Dr. Vij across 28 procedure codes in 2024, for 358 Medicare patients. Medicare paid $336,717 for them.

CMS counts 358 Medicare patients who saw Dr. Vij in 2024. The largest group is 65 to 74, with 179 patients. 72% of them have high blood pressure, and 69% have high cholesterol. 11% are also on Medicaid. Their average risk score is 3.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vij's median patient age at 71, with 46% women.

In 2024, Dr. Vij wrote 2,266 Medicare Part D claims for 199 patients. 77% of them were for generic drugs. CMS names the drug for 1,943 of them, across 43 drugs with 11 or more claims each, at $7,830,845 in total drug cost. In 2023, CMS named 1,823 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Vij for performance year 2024, reported as part of a group. Dr. Vij accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 62 papers to Dr. Vij, published from 2017 to 2020. 2019 was the busiest year, with 19. The most frequent topics are Multiple Myeloma, Hematopoietic Stem Cell Transplantation and Transplantation, Autologous. Dr. Vij has published most often in Clin Lymphoma Myeloma Leuk. Dr. Vij's most frequent co-authors are John F. Dipersio, MD, Mark Andrew Schroeder, MD and Armin Ghobadi, MD.

Dmand AI links Dr. Vij to 3 clinical trials. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Hematologic Neoplasms. Sanofi sponsors the most, 3. Open Payments lists research payments to Dr. Vij that name 3 trials.

CMS Open Payments shows 387 general payments to Dr. Vij from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Sanofi and Genzyme US Companies paid the most, $53,561. It also lists 32 research payments totaling $31,241 from 2016 to 2025, naming 3 clinical trials.